Citations (4)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Daisuke Yabe & Yutaka Seino. (2016) Alogliptin for the treatment of type 2 diabetes: a drug safety evaluation. Expert Opinion on Drug Safety 15:2, pages 249-264.
Read now
Read now
Articles from other publishers (3)
Ivan O. Maslov, Tatiana V. Zinevich, Olga G. Kirichenko, Mikhail V. Trukhan, Sergey V. Shorshnev, Natalya O. Tuaeva, Maxim A. Gureev, Amelia D. Dahlén, Yuri B. Porozov, Helgi B. Schiöth & Vladimir M. Trukhan. (2022) Design, Synthesis and Biological Evaluation of Neogliptin, a Novel 2-Azabicyclo[2.2.1]heptane-Based Inhibitor of Dipeptidyl Peptidase-4 (DPP-4). Pharmaceuticals 15:3, pages 273.
Crossref
Crossref
Supratik Bhattacharyya, Aditya Bikram Mishra & Maneesha Khalse. (2021) CLINICAL EFFECTIVENESS OF FIXED DOSE COMBINATION OF EMPAGLIFLOZIN AND LINAGLIPTIN (EMPA/LINA) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS UNWILLING TO CONTINUE BASAL INSULIN THERAPY: A REAL-WORLD EXPERIENCE IN INDIAN SETTING. INDIAN JOURNAL OF APPLIED RESEARCH, pages 42-44.
Crossref
Crossref
Gabrielle Kéfrem Alves Gomes, Mariana Linhares Pereira, Cristina Sanches & André Oliveira Baldoni. (2019) Post-marketing Study of Linagliptin: A Pilot Study. Frontiers in Pharmacology 10.
Crossref
Crossref